LOL—true! I haven’t been listing IDIX’s NS5A inhibitor in the “HCV: Most Likely to Succeed” compilation because it doesn’t yet have a code name; however, I’ve been listing several other preclinical compounds that don’t yet have a name. In other words, I’ve been applying a double standard that penalized IDIX. This double standard will now end!
Market Data 
Markets 
AI
